Form 4: AngioDynamics SVP Laura Piccinini Reports Stock Transactions Following Performance Share Unit Vesting
SEC Form 4
Laura Piccinini, SVP International at AngioDynamics, reports the acquisition and disposition of common stock related to the vesting of performance share units.
Summary
- On July 17, 2024, Laura Piccinini, SVP International at AngioDynamics, acquired 4,439 shares of common stock through the vesting and settlement of performance share units granted on July 21, 2021.
- On the same day, she disposed of 2,485 shares to satisfy tax withholding obligations related to the vesting of these performance share units at a price of $7.4.
- Following these transactions, Piccinini directly owns 40,006 shares of AngioDynamics common stock.
- The performance share units were granted on July 21, 2021, with the number of shares earned based on performance metrics for fiscal years 2022, 2023, and 2024.
- The compensation committee determined that 4,439 shares were issued, and the remaining shares were forfeited.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It reflects a routine transaction related to executive compensation. The vesting of shares suggests performance targets were met, which is mildly positive, but the tax-related sale is neutral.
Positives
- The vesting of performance share units indicates that certain performance goals were met, which could be viewed positively.
Negatives
- The disposition of shares to cover tax obligations could be seen as a slight negative, although it's a common practice.
Industry Context
Form 4 filings are standard disclosures for company insiders and provide transparency into their trading activities. This filing indicates routine compensation-related stock transactions.
Comparison to Industry Standards
- Performance-based equity compensation is a common practice among publicly traded companies to align management's interests with those of shareholders.
- The vesting and settlement of performance share units are typical components of executive compensation packages in the medical device industry.
- Companies like Medtronic, Boston Scientific, and Abbott also utilize similar equity-based compensation plans for their executives.
Stakeholder Impact
- The transactions have a minor impact on shareholders as they reflect insider trading activity related to compensation.
Key Dates
| Date | Description |
|---|---|
| 07/21/2021 | Date of the original grant of performance share units to the reporting person. |
| 07/17/2024 | Date of the transaction involving the acquisition and disposition of shares. |
| 08/02/2024 | Date of signature of the report. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.